Syros Highlights Anticipated 2024 Milestones For Tamibarotene
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals has announced its anticipated milestones for 2024 regarding Tamibarotene. The company expects to complete enrollment of 190 patients for the primary analysis in the SELECT-MDS-1 Phase 3 trial in the first quarter of 2024, with pivotal CR data anticipated by mid-fourth quarter of 2024. Additional data from the SELECT-AML-1 Phase 2 trial is also expected in 2024, following initial data showing a 100% CR/CRi rate and a favorable tolerability profile. Syros has also strengthened its balance sheet with approximately $45.0 million in gross proceeds from recent equity financing, extending its cash runway into the second quarter of 2025.
January 08, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syros Pharmaceuticals is on track to complete patient enrollment for a Phase 3 trial and expects pivotal data by late 2024, with a strengthened balance sheet from recent financing.
The positive progress in clinical trials and the successful equity financing which extends the company's cash runway are likely to be viewed favorably by investors. The anticipation of pivotal data by the end of 2024 could drive investor optimism and potentially increase the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100